Work Medical, Novabioplus Unveil Four AI-Driven Protein Design Projects with BioTokens
On April 13, 2026, Work Medical Technology Group partnered with Shanghai Novabioplus to co-develop four AI-driven protein and molecule design projects, including membrane protein and peptide design, integrating AI algorithms with Novabioplus’ extensive protein datasets. The collaboration also establishes a “BioToken” digital asset model to monetize biological data.
1. Strategic Cooperation Agreement
On April 13, 2026, Work Medical Technology Group entered a strategic cooperation agreement with Shanghai Novabioplus Biotechnology to develop a “Data-Model-Application” trinity of intelligent medical models. The partnership integrates Work Medical’s AI-driven healthcare digital transformation with Novabioplus’ protein data repositories and reagent platforms.
2. Four AI+ Protein Design Initiatives
The collaboration encompasses four major AI+ projects: AI-based membrane protein design, AI-driven antibody sequence optimization, AI-enabled enzyme molecule design, and AI-powered peptide design. These initiatives combine advanced AI algorithms with multi-dimensional biological data to enable precise biomolecular design and functional simulation.
3. BioToken Assetization Model
The partners will create “BioTokens” by converting AI-enhanced protein sequences, functional data, and lab datasets into tradable digital assets. This BioToken ecosystem aims to unlock long-term commercial value of biological R&D outputs through an intelligent digital protein database.
4. Strategic Implications and Value Creation
This alliance advances Work Medical’s Healthcare + Web3 + AI strategy and positions it as a digital asset operator in life sciences. Through potential joint investments and resource integration, the partnership seeks to accelerate clinical translation, expand biopharmaceutical R&D capabilities, and drive new revenue streams.